The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
B-catenin mutations and the response of advanced hepatocellular carcinoma to immune checkpoint inhibitors.
 
Himil Mahadevia
Stock and Other Ownership Interests - Abbvie; Allogene Therapeutics; Bristol-Myers Squibb; Cardiol Therapeutics; Crispr Therapeutics; IMV; Pfizer; Xeris Pharmaceuticals
 
Robin John Lester Imperial
No Relationships to Disclose
 
Beau Toskich
Stock and Other Ownership Interests - Vivos Therapeutics
Honoraria - Boston Scientific (Inst); BTG (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boston Scientific (Inst); Eisai (Inst); Genentech (Inst); Histosonics (Inst); Johnson & Johnson (Inst); Sirtex Medical (Inst)
Research Funding - AstraZeneca (Inst); Boston Scientific (Inst); Genentech (Inst); Johnson and Johnson (Inst)
Travel, Accommodations, Expenses - Boston Scientific (Inst)
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Boston Scientific; BTG; BTG; Celgene; Eisai; Exelixis; Exelixis; Genentech/Roche; Incyte (Inst); Ipsen; Merrimack; QED Therapeutics; Vicus Therapeutics
Research Funding - Agios (Inst); ARIAD (Inst); ArQule (Inst); AstraZeneca (Inst); Basilea (Inst); FibroGen (Inst); Gritstone Bio (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst); Turnstone Bio (Inst); Vyriad (Inst)